



Pfizer Australia  
Level 15-18  
151 Clarence Street  
Sydney NSW 2000

30 June 2020

The Hon. Greg Hunt MP  
Minister for Health  
PO Box 6022  
Parliament House  
Canberra ACT 2600

Dear Minister Hunt,

Thank you for your steadfast leadership during this global health crisis. Pfizer stands in solidarity with all patients around the world and in Australia currently affected by COVID-19, and with the governments, organisations, and health professionals working to respond to the pandemic. Pfizer is committed to playing its part and has created a crisis team of our leading virologists, biologists, chemists, clinicians, epidemiologists, vaccine experts, pharmaceutical scientists, and other key experts to focus solely on addressing this pandemic. I would like to take this opportunity to provide an overview of our candidate vaccine development and manufacturing program and request a meeting with you to open discussions regarding your planning for potential COVID-19 vaccination programs.

**Vaccine Development.** In collaboration with BioNTech, Pfizer is working closely with regulatory authorities to develop, test and manufacture a potential mRNA-based vaccine that, if approved, could be deployed at unprecedented speed for the prevention of COVID-19 infection. We are leveraging our decades of scientific expertise in pioneering vaccine discovery and development to respond to this global health crisis.

Pfizer and BioNTech are working with regulatory authorities to advance multiple COVID-19 vaccine candidates into human clinical testing with our R&D program now underway globally. The Phase 1/2 study is unique in that it is testing four vaccine candidates simultaneously, each representing a unique combination of mRNA format and target antigen. Each of those four vaccine candidates is potentially being tested in three different doses and two different age populations in a single Phase 1/2 study. The design of the trial allows us to move urgently, while preserving the highest quality and safety standards.

**Vaccine Delivery.** We are actively scaling up our manufacturing capacity and distribution infrastructure to be ready to bring a candidate vaccine to the world faster than we have ever done before. By doing many steps in the manufacturing process in parallel, rather than sequentially, we have the potential to supply millions of vaccine doses by the end of 2020, subject to technical success and regulatory approvals, then rapidly scale up to produce hundreds of millions of doses in 2021.

Vaccines are an important part of the long-term solution for ending this pandemic and we are committed to bring our deep heritage in vaccine development, remarkable reach and scale, and capital resources to serve the millions of people around the world impacted by this devastating illness.



Should our candidate vaccine be successful in clinical trials and receive regulatory approval or emergency use authorisation, we want to work with governments, as well as other vaccine manufacturers and global bodies, to supply the world as quickly as we can.

I would welcome an opportunity to discuss our candidate vaccine development in more detail, and open discussions on how we might work together to support planning for potential COVID-19 vaccinations in Australia and continue to build a strong partnership for the future.

Pfizer's <sup>s 47F</sup> will be in touch to schedule a meeting. I look forward to meeting you and working with you into the future.

Yours sincerely

<sup>s 47F</sup>

Pfizer Australia & New Zealand

THIS DOCUMENT HAS BEEN RELEASED UNDER  
THE FREEDOM OF INFORMATION ACT 1982 (C'TH)  
BY THE DEPARTMENT OF HEALTH